All updated as on -
From a starting point of USD 344.5 billion in 2022, the Global Biologics Market Size is projected to reach a whopping USD 517.3 billion by 2030, expanding at a compound annual growth rate (CAGR) of 4.7%.
Companies' heavy investment in upgraded production facilities has led to a fast expanding biologics sector. It is expected that the versatility of biologics in the treatment of chronic diseases would contribute to the growth of the market. Many different types of organisms, including bacteria, mammals, and transgenic plants and animals, are used to produce these goods. The ease with which microbial cell lines can be obtained, as well as the versatility and low cost of cultivating them, contribute to their widespread use in biologic manufacturing. The biologics market contains a wide variety of goods, such as monoclonal antibodies (MAbs), vaccines, recombinant proteins, antisense, RNAi, and molecular therapy. Due to their usefulness in a range of therapeutic contexts, including the treatment of illness and clinical investigation, MAbs are expected to dominate the market. Diagnostics, therapies, and protein purification are just few of the many applications of monoclonal antibodies (MAbs) in the biological sciences.
Once upon a time, only a select few businesses were capable of handling every step of the biologics production process. Since there are now many manufacturers of biologics, this field has advanced greatly during the past decade. Nanobodies, recombinant DNA, synthetic vaccines, fusion proteins, soluble receptors, immunoconjugates, and immunotherapeutics are only a few examples of the novel items discovered in this field. Because of how biologics have revolutionised disease therapy, scientists have numerous chances to explore hybrid architectures that combine biologics with well-defined chemical entities. The extraordinary success of biologics can be attributed in part to the rapid development of biotechnology. Biologics include substances including vaccines, cell/tissue therapies, enzymes, hormones, interleukins, peptides, antibodies, coagulation proteins, fusion proteins, growth factors, interferon, liposomes, and antibodies. Businesses are interested in this area because biologics can interact with places that small chemicals have so far been unable to access. Biologics also appear to have a more positive impact on the economy as a whole than small molecules, which suggests that they have a promising commercial future. Biologics are also less likely to lose their effectiveness over time than tiny molecules, making them more convenient to use.
The constant development of biotechnology and biomedical science techniques has allowed for the manufacture of biologics to treat a wide range of chronic diseases. Scientists hoped to learn more about protein discovery and expression, cell line creation, and potential engineering applications by making these adjustments. Several methods have emerged in biotechnology for manufacturing self-adjuvant antigen-adjuvant fusion protein subunit vaccines. The development of new vaccines is thought to benefit from characterised platforms of novel adjuvants. Nanosystems have also seen growing use in recent years because to the delivery challenges connected with mRNA treatments for disease treatment being significantly reduced.
Report Coverage
Global Biologics research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Biologics report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Biologics competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Biologics market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Biologics market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Biologics market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Biologics market based on the below-mentioned segments:
Global Biologics Market, By Source
Global Biologics Market, By Products
Global Biologics market, By Manufacturing
Global Biologics market, Regional Analysis
Companies' heavy investment in upgraded production facilities has led to a fast expanding biologics sector. It is expected that the versatility of biologics in the treatment of chronic diseases would contribute to the growth of the market. Many different types of organisms, including bacteria, mammals, and transgenic plants and animals, are used to produce these goods. The ease with which microbial cell lines can be obtained, as well as the versatility and low cost of cultivating them, contribute to their widespread use in biologic manufacturing. The biologics market contains a wide variety of goods, such as monoclonal antibodies (MAbs), vaccines, recombinant proteins, antisense, RNAi, and molecular therapy. Due to their usefulness in a range of therapeutic contexts, including the treatment of illness and clinical investigation, MAbs are expected to dominate the market. Diagnostics, therapies, and protein purification are just few of the many applications of monoclonal antibodies (MAbs) in the biological sciences.
Once upon a time, only a select few businesses were capable of handling every step of the biologics production process. Since there are now many manufacturers of biologics, this field has advanced greatly during the past decade. Nanobodies, recombinant DNA, synthetic vaccines, fusion proteins, soluble receptors, immunoconjugates, and immunotherapeutics are only a few examples of the novel items discovered in this field. Because of how biologics have revolutionised disease therapy, scientists have numerous chances to explore hybrid architectures that combine biologics with well-defined chemical entities. The extraordinary success of biologics can be attributed in part to the rapid development of biotechnology. Biologics include substances including vaccines, cell/tissue therapies, enzymes, hormones, interleukins, peptides, antibodies, coagulation proteins, fusion proteins, growth factors, interferon, liposomes, and antibodies. Businesses are interested in this area because biologics can interact with places that small chemicals have so far been unable to access. Biologics also appear to have a more positive impact on the economy as a whole than small molecules, which suggests that they have a promising commercial future. Biologics are also less likely to lose their effectiveness over time than tiny molecules, making them more convenient to use.
The constant development of biotechnology and biomedical science techniques has allowed for the manufacture of biologics to treat a wide range of chronic diseases. Scientists hoped to learn more about protein discovery and expression, cell line creation, and potential engineering applications by making these adjustments. Several methods have emerged in biotechnology for manufacturing self-adjuvant antigen-adjuvant fusion protein subunit vaccines. The development of new vaccines is thought to benefit from characterised platforms of novel adjuvants. Nanosystems have also seen growing use in recent years because to the delivery challenges connected with mRNA treatments for disease treatment being significantly reduced.
Report Coverage
Global Biologics research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Biologics report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Biologics competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Biologics market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Bristol Myers Squibb Company, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Johnson & Johnson Services Inc., Hoffmann La Roche Ltd, etc. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Biologics Market from 2021 to 2030.
- Market Forecast for Biologics Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Biologics competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Biologics
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Biologics market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Biologics market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
- Bristol-Myers Squibb Company
- Merck KGaA
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc
- Johnson & Johnson Services Inc
- Hoffmann La Roche Ltd
Primary Target Market
- Market Players of Biologics
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Biologics market based on the below-mentioned segments:
Global Biologics Market, By Source
- Mammalian
- Microbial
Global Biologics Market, By Products
- Monoclonal Antibodies
- Vaccines
- Recombinant Proteins,
- Antisense
- RNAi
Global Biologics market, By Manufacturing
- In-house
- Outsourced
Global Biologics market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive biologics market market research and competitor analysis for your business to help you develop more profound insights into the biologics market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the biologics market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.